Pulmonary Embolism in COVID-19 Patients in France

Quick Takes

  • Pulmonary embolism (PE) in the context of coronavirus disease 2019 (COVID-19) appears to be driven largely by inflammation and coagulopathy rather than by traditional risk factors for thromboembolism.
  • Study results suggest that anticoagulation therapy with prophylactic dosing during hospitalization or therapeutic dosing before admission could reduce occurrence of PE.
  • Findings are consistent with international guidelines, which recommend prophylactic anticoagulation, unless contraindicated, for hospitalized adult and adolescent patients with COVID-19.

Study Questions:

What risk factors are associated with development of PE in patients hospitalized for COVID-19?

Methods:

The retrospective, observational Critical Covid-19 France study evaluated consecutive adult patients diagnosed with severe acute respiratory syndrome coronavirus 2 who were admitted to any of 24 hospitals in France between February 26 and April 20, 2020. Patients underwent computed tomographic pulmonary angiography (CTPA) if they required supplemental oxygen and had limited disease extension; patients also underwent CTPA if unenhanced computed tomography failed to explain severity of respiratory failure. The primary study outcome was PE confirmed by CTPA. Other outcomes of interest included death, intensive care unit (ICU) admission, invasive mechanical ventilation, noninvasive ventilation, and PE severity. The study excluded patients who were admitted directly to ICU upon hospital admission, those who did not undergo CTPA for diagnosis of PE, and patients without PE who remained hospitalized at the end of the study.

Results:

The study included 1,240 patients, of whom 103 (8.3%) were diagnosed with PE. Patients with PE more often required transfer to ICU (31.1% vs. 13.5%; p < 0.001) or mechanical ventilation (24.3% vs. 7.3%; p < 0.001) than patients without PE. Presence of PE was not associated with increased mortality. PE was characterized as high risk in 31%, intermediate-to-high risk in 7%, intermediate-to-low risk in 12%, and low risk in 51%. In 78% of patients, PE was diagnosed within 48 hours of hospital admission. In patients diagnosed with PE, median time from hospital admission to ICU transfer was 2 days; median time to death without ICU transfer was 6.4 days. Univariate analysis showed that increased risk of PE was associated with male gender, history of stroke, atrial fibrillation, presence of chest pain, longer time from onset of symptoms to hospitalization, increased leukocytes and platelets, elevated C-reactive protein, higher D-dimer, severe pulmonary lesions on computed tomography, higher fraction of inspired oxygen, and lower partial pressure of oxygen. PE incidence was lower in patients who received therapeutic dose anticoagulation prior to admission and in patients treated with prophylactic dose anticoagulation during hospitalization. In the multivariate analysis, factors associated with increased risk of PE included therapeutic anticoagulation prior to admission, prophylactic dose of anticoagulation during hospitalization, elevated C-reactive protein, time from onset of symptoms to hospitalization, and male sex.

Conclusions:

This multicenter study in France identified independent clinical and biological risk factors for development of PE in patients with COVID-19. No association was found with traditional thromboembolic risk factors; rather, the study findings suggest that inflammation and coagulation have a major influence on the development of PE in patients with COVID-19.

Perspective:

Recent international guidelines have recommended pharmacological prophylaxis, unless contraindicated, in adult and adolescent patients hospitalized with COVID-19. Guidelines from the International Society on Thrombosis and Haemostasis published online have suggested low molecular weight heparin as the preferred agent, with intermediate-dose low molecular weight heparin or prophylactic-dose unfractionated heparin as alternatives. New oral anticoagulants may interact with some investigational drugs such as lopinavir/ritonavir and should be avoided in such cases. The Critical Covid-19 France study supports the above recommendations and provides additional evidence that coagulopathy and inflammation are drivers for development of PE in patients with COVID-19.

Clinical Topics: Anticoagulation Management, COVID-19 Hub, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Vascular Medicine, Interventions and Imaging, Interventions and Vascular Medicine, Computed Tomography, Nuclear Imaging

Keywords: COVID-19, Coronavirus, Pulmonary Embolism, Anticoagulants, severe acute respiratory syndrome coronavirus 2, Tomography, Spiral Computed, Heparin, Heparin, Low-Molecular-Weight


< Back to Listings